Skip to main content

ORIGINAL RESEARCH article

Front. Med., 15 March 2021
Sec. Geriatric Medicine
This article is part of the Research Topic Reducing the Burden of Age-related Disease in relation to Osteoporosis, Sarcopenia and Osteosarcopenia View all 13 articles

Phase Angle Cut-Off Points and Their Association With Sarcopenia and Frailty in Adults of 50–64 Years Old and Older Adults in Mexico City

  • 1Health Department, Ibero American University, Mexico City, Mexico
  • 2Instituto Nacional de Geriatría, Mexico City, Mexico

Background: In recent studies, the usefulness of the phase angle (PA) to assess geriatric conditions such as sarcopenia and frailty has been evaluated. However, there are no useful cut-off points for clinical research and/or practice.

Objective: To analyze PA cut-off points associated with sarcopenia and frailty in adults of 50-64 years old and older adults in Mexico City.

Design: Cross-sectional analysis of the FraDySMex cohort study (Frailty, Dynapenia, and Sarcopenia in Mexican Adults).

Setting and Participants: 498 people were included, 78.7% women, aged 71.1 ± 9.5 years. Methods: The sarcopenia measurements were made according to the European Working Group on Sarcopenia in Older People (EWGSOP) (2019) (by dynamometer to evaluate hand grip strength and dual energy X-ray absorptiometry (DXA) for appendicular muscle mass), and the frailty through the physical frailty phenotype with cut-off points adjusted to the Mexican population. The PA was evaluated by bioelectrical impedance analysis (BIA), tetrapolar to 50 Hz, other variables such as socio-demographic, comorbidity, cognitive status, and functional dependence were evaluated.

Results: The prevalence of frailty was 10.6% and sarcopenia 10.0%. The mean of the PA was 4.6° ± 0.70°. The PA cut-off point for frailty in adults 50 to 64 years was ≤4.3° [sensitivity (S) = 91.95%, specificity (Sp) 66.77%, AUROC (Area Under the Receiver Operating Characteristic) curve = 0.9273 95% CI (0.8720-0.9825)]; the PA cut-off point for sarcopenia was ≤4.3 [S = 91.95%, Sp = 66.77%, AUROC = 0.9306 95% CI (0.8508-1.000)]. The PA cut-off for frailty in adults ≥ 65 years was ≤4.1° [S = 72.37%, Sp 71.43%, AUROC = 0.7925 95%, CI (0.7280-0.8568)] for sarcopenia was ≤4.1° [S = 72.76%, Sp 73.81%, AUROC = 0.7930 95% CI (0.7272-0.8587)]. These cut-off points showed a significant association between PA with frailty (OR 4.84; 95% CI 2.61-8.99) and sarcopenia (OR 8.44; 95% CI 3.85-18.4) after adjusted by age, sex, BMI, comorbidity index and cognitive impairment.

Conclusions and Implications: These cut-off points of PA could be useful for the screening of sarcopenia and frailty in Mexican adults of 50 years and older in centers that have BIA.

Introduction

The bioelectrical impedance analysis (BIA) is a relatively simple, inexpensive, fast, non-invasive, and reliable technique to assess body composition (1, 2). The BIA technique is based on the measurement of impedance made up of resistance (R) and reactance (Xc) through one or more electrical frequencies. The tangent area between resistance and reactance in a series or parallel circuit is called the phase angle (PA). The R and Xc values allow us to obtain, through various prediction equations, fat free mass (FFM), total body water (TBW), and fat mass (FM). The phase angle has its advantages, since it allows us to directly assess the permeability of the membrane by measuring intra and extracellular electrical flows, which makes it independent of the state of hydration, body weight, and does not require calculation using predictive models (3).

The PA represents an effective marker to preventively detect health conditions, as well as mortality, morbidity and lower survival with an established disease (4, 5). Due to its usefulness and simplicity, recent studies have explored PA cut-off points which can be effective in timely detecting conditions related to the functionality of the older adults, such as sarcopenia and frailty. Sarcopenia is the progressive and generalized loss of muscle mass and strength with the risk of adverse effects such as physical disability, poor quality of life and higher mortality (6). Frailty is the decrease in physiological reserve that would result in an increased risk of disability, loss of resistance and increased vulnerability to adverse events in individuals, which manifests itself in increased morbidity and mortality (7). According to a systematic review and meta-analysis, the prevalence of sarcopenia has been reported to be 10% for men (95% CI: 8-12%) and women (95% CI: 8-13%) respectively (8). According to a sample of adults over 60 years from Mexico City, the prevalence of sarcopenia was 9.7% and frailty was 15.7% (9, 10). Both conditions have serious clinical implications and, if detected in time, can be reversed with the support of an adequate treatment (11).

Recently the phase angle has been suggested as a possible effective biomarker for the prediction of both clinical conditions (5, 12). For example, Marini et al. (13) correlated a lower PA 5.2° in women and 5.0° in men with pre-sarcopenia defined by their muscle mass in their lower and upper extremities muscle mass <7.26 kg/m2 for men and 5.45 kg/m2 for women (14). Likewise, in a Japanese population of older adults who were hospitalized, Yamada et al. (15). found a PA of 4.05° and 3.55° in men and women, respectively, being effective indicators for muscle function (measured by ultrasonography for the quality of muscle mass, muscle strength, and physical performance). Other authors have reported different cut-off points of PA for sarcopenia: 4.55°, 5.6° for men and 5.8° for women (16, 17). The PA has also been correlated with muscular arm strength in people with cirrhosis (r = 0.53) and cancer (men r = 0.59, women r = 0.48) as well as with a knee extension (r = 0.4) (12, 18, 19). Similarly, a lower PA has been correlated with a greater degree of physical frailty, according to the Fried scale (r = −0.31) and ETF (Essential Frailty Toolset) (r = −0.31) (5).

Although it is true that low PA values have proven to be predictive of negative outcomes, there is currently a wide variability in reported cut-off points. This variability may depend on determinants of PA such as sex, age, BMI and the type of clinical condition or disease (18, 19). In addition, it is important to consider other parameters such as the type of population studied (hospital, community, homes for the elderly), among others. To our knowledge, there are no PA cut-off points for adults between 50 and 64 years old and older adults, adjusted by sex and BMI, related to health conditions that allow its use in different clinical and research settings. Therefore, the objective was to report the cut-off points associated with sarcopenia and frailty in adults of 50-64 years and Mexican older adults.

Materials and Methods

Design and Study Population

This study, a secondary analysis of the FraDySMex study (Frailty, Dynapenia and Sarcopenia in Mexican Adults), is a cohort of adults living in the community of two municipalities of Mexico City consisting of men and women over 50 years of age, all of whom are able to move with or without assistive devices and able to answer the questions of the study questionnaire by themselves or with the help of a caregiver if the score of the mini-mental state examination (MMSE) with 10 points or less. People with a total functional dependence, presence of edema in their extremities, current intake of diuretics, presence of fever, diarrhea, pacemaker carriers, cancer diagnosis of 5 years or less, were excluded. The study consisted of objective evaluations by the multidisciplinary team of the Research Laboratory in Functional Evaluation of the National Institute of Geriatrics in Mexico City. More details of the design, recruitment and selection of the FraDySMex study of participants can be found in another study (20). The study was approved by the Ethics Committee of the Mocel de Angeles General Hospital and enrolled in the National Institute of Geriatrics with the number DI-PI-002/2014. Informed signed consent was obtained by all individuals before the study.

Measurements

Phase angle. It was evaluated by the 50 Hz frequency bioelectrical impedance tetrapolar, brand SECA® model mBCA 514.

Diagnosis of Sarcopenia and Frailty

Sarcopenia was defined according to the criteria of the EWGSOP 2019 (6) adjusted to our population considering the low muscle strength (criterion 1), low muscle quantity (criterion 2) and the low physical performance (criterion 3). Probable sarcopenia is identified by criterion 1, diagnosis is confirmed by additional documentation of criterion 1 and 2 and criteria 1, 2, and 3 are all met, sarcopenia is considered severe. For this analysis, it was classified as sarcopenic when had sarcopenia confirmed and sarcopenia severe and as non-sarcopenic when had sarcopenia probable or don't present any criterion.

Muscle strength was evaluated with manual hand grip strength using the hydraulic JAMAR dynamometer, Lafayette, IN. Three measures of the dominant hand were taken and the highest was considered for the analysis. For low muscle strength, the lowest quartile for grip strength (kg) was considered adjusted for BMI (kg / mts2) and sex (Table 1). Gait speed (GS) was recorded at a habitual gait of 6 meters on a Gait Rite instrumented mat (platinum 20) (204 x 35.5 x 0.25 inches, 100 Hz sampling rate). The GS cut-off points for our population were adjusted for height (m) and sex based on the lowest quintile (Table 1). Muscle quantity was evaluated with appendicular muscle mass (ASM) through the dual energy X-ray absorptiometry (DXA), (Hologic Discovery-WI; Hologic Inc., Bedford-MA; to define low muscle mass based on the lowest quintile for sex (Table 1).

TABLE 1
www.frontiersin.org

Table 1. Components and cut-off points used for the diagnosis of sarcopenia.

Physical Frailty

Using the Fried's criteria a score ≥ 3 was consider as frailty (21). The grip strength and gait velocity were defined as described in the sarcopenia variable. Low physical activity was defined using the lowest quintile of kilocalories per week obtained through the physical activity questionnaire for older adults (CHAMPS), <545.7 for men and <481.2 kcal/week for women (22). The following question was used for the variables of involuntary weight loss: In the last year, have you unintentionally lost 5 kg (or 5% of your weight) or more? For the low energy or exhaustion variable, 2 questions of the CES D-7 scale Mexican version were used (does it feel like everything you do is an effort? and the one that questioned if the person felt like doing nothing. These questions were answered as never or almost never, sometimes (1 to 2 times a week), frequently (3 to 4 days a week) and 1 (always or almost always (5 to 7 days a week) (23).

Other Variables

Other measures obtained were the following: depressive symptoms using the CES scale item D-7 (Center for Epidemiologic Studies, Depression Scale, Mexican version) (depression was considered if it scored ≥5) (23). Cognitive state was assessed using the MMSE (cognitive impairment was considered when it scored ≤ 23 points with ≤ 5 of school education, ≤ 19 points he/she was in school between 1 and 4 years, ≤ 16 without schooling or <1 year of schooling) (24, 25). Comorbidity was assessed using the comorbidity index adapted to Mexican Spanish (26, 27). Information about schooling in years (<10 y vs. ≥ 10 y), history of falls (one or more falls in the last year), low physical performance was assessed by the short physical performance battery (SPPB) using ≤ 8 points as the cut-off point (28). Functional dependence was also assessed using the Lawton scale for instrumental activities of daily life (IADL) (≥ 1 activities) and the Barthel scale for basic activities of daily living (BADL) (≤95 points) (29, 30). Malnutrition was evaluated with Mini Nutritional Assessment (MNA) scale and cutoff ≤ 23 points was used to define the risk of malnutrition. Other measures of body composition were also obtained through DXA, such as the percent total body fat considering obesity when calculated as > 30% in men and > 40% in women, bone mineral density of the hip and spine using the WHO cut-off points to define osteopenia and osteoporosis (31). Similarly, anthropometric measurements were obtained such as weight (kg), height (mts), calf and mild arm circumference (cm), and BMI (kg / mts2).

Statistical Analysis

The data were analyzed using the Stata 12.0 statistical package. Descriptive statistics are reported as means ± SD for continuous variables and as frequencies for categorical variables. Some continuous variables were dichotomized for its analysis according to cut-off points previously established in the literature as exposed in the variable section. Determination of the cut-off points of the PA. The cut-off points were explored by sarcopenia and frailty in both aged groups) using sensitivity (S), specificity (Sp), and AUROC curve analysis.

To show the association of these cut-off points of PA with sarcopenia and frailty, were included in a simple and adjusted logistical regression. The results are shown as odds ratio (OR) with the respective 95% confidence intervals (CI); the final model was adjusted by sex and other variables reported in the literature that are associated with phase angle, sarcopenia, and frailty. To evaluate the goodness of fit of the models, we use Hosmer-Lemeshow goodness of fit test and AUCROC curve. The interaction and collinearity between the independent variables of the model were also evaluated.

Results

The analytical sample consisted of 606 after excluding 63 participants younger than 50 years, 39 participants not submitted to DXA or BIA evaluation and 6 participants not submitted to hand-grip test (Figure 1). 498 adults over 50 years old were included, with 78.7% females (n = 392); the mean age was 71.1 ± 9.5 (SD) years and 50.3% had low schooling. The following prevalence's were observed in the total sample: depressive symptoms (41.8%), cognitive impairment (11.2%), higher comorbidity (24.9%), falls (40.9%), low physical performance (34%), functional dependence by IADL (16.4%) and BADL (8.0%), risk of malnutrition (24.6%), osteopenia/osteoporosis (47.0%), and obesity (70.1%). A prevalence of frailty of 10.6% and sarcopenia of 10.0% were found in the total sample (Table 2). The average of the PA in the total adults was 4.6° ± 0.70° (SD) and 5.0 ± 0.61 in the younger adults (50 to 65 years) and 4.3 ± 0.70 in the older adults (over 65 years), p = 0.0000. The PA cut-off points were generated for the two conditions (frailty and sarcopenia) stratified by age (adults with 50 to 65 years and adults over 65 years) reported (Table 2); the PA cut-off for frailty in adults 50 to 65 years was ≤4.3°, S = 91.95%, Sp 66.77% LHR (likelihood ratio) (+) 2.7584, LHR (-) 0.1208; AUROC = 0.9273 95% CI (0.8720-0.9825) (Table 3). PA cut-off for sarcopenia in the adults 50 to 65 years was ≤4.3°, S = 91.95%, Sp 66.77% LHR (+) 2.7589, LHR (-) 0.1208; AUROC = 0.9306 95% CI (0.8508-1.000) (Table 3). The PA cut off for frailty in adults over 65 years was ≤4.1°, S = 72.37%, Sp71.43% LHR (+) 2.5329, LHR (-) 0.3868; AUROC = 0.7925 95% CI (0.7280-0.8568). PA cut-off for sarcopenia in adults over 65 years was ≤4.1°, S = 72.76%, Sp= 73.81% LHR (+) 2.7788, LHR (-) 0.3691; AUROC = 0.7930 95% CI (0.7272-0.8587) (Table 3).

FIGURE 1
www.frontiersin.org

Figure 1. Flowchart of the FraDySMex study (Frailty, Dynapenia and Sarcopenia in Mexican Adults). BIA (bioelectrical impedance) and DXA (dual energy X-ray absorptiometry).

TABLE 2
www.frontiersin.org

Table 2. General characteristics (n = 498).

TABLE 3
www.frontiersin.org

Table 3. Criterion validity of phase angle vs. frailty and sarcopenia stratified by age.

The Table 4 included two models, the first adjusted model show a significant association between the low phase angle cut-off point ≤ 4.3 in the adults between 50 to 65 years old and ≤4.1 in the adults over 65 years) and frailty (OR 4.84; 95% CI 2.61-8.99); in the second model show a significant association with sarcopenia (OR 8.44; 95% CI 3.85-18.4); both models were adjusted by sex, BMI, comorbidity index and cognitive impairment.

TABLE 4
www.frontiersin.org

Table 4. Association between phase angle and sarcopenia and frailty.

Discussion

Our results show two new PA cut-off points for sarcopenia, in the adults 50 to 65 years was ≤4.3° with a high S (91.95%) and AUROC = 0.9306 95% CI (0.8508-1.000) both low Sp (66.77%). In adults over 65 years was ≤4.1° with acceptable S = 72.76% and Sp 73.81% and AUROC = 0.7930 95% CI (0.7272-0.8587) both cut-off points can be used for the screening of sarcopenia; in this regard a few studies have been conducted on the relationship between PA and sarcopenia. In the study of Basile et al. (12), with 207 people (mean age 76.2 ± 6.7 years) it was shown that there is an inverse correlation between the muscle mass (y = 3.16 + 0.08x; r = 0.49; P < 0.001) and muscular strength (y = 3.04 + 0.25x; r = 0.60; P < 0001) with the PA without specifying cut-off points. Previously Kilic et al. (16), showed that a cut-off point of <4.55° with an AUROC of 0.703 (P < 0.0001), with a sensitivity of 70% and specificity of 64.9% were acceptable for screening sarcopenia. However, in other study by Santana et al. (17), with 146 hospitalized people (age 71.6 ± 7.6 years) did not find an association between PA values and sarcopenia components. The most recent study to date on this association by Pessoa et al. (32) with 94 women, did not find an association with sarcopenia OR = 1.50 (0.520–4.319), low muscle mass index OR = 1.50 (0.520–4.319), low HGS OR = 3.15 0.954–10.401). This study mentions that the small sample size could impact the lack of association in PA and sarcopenia.

Our study proposes these cut-off points (≤4.3° for adults 50 to 65 years and ≤4.1° for adults over 65 years) based on their criterion validity through the following properties: sensitivity, specificity, AUROC and LHR +, LHR-. However, to strengthen this criterion validity, the low PA variable was included as independent variable in a model adjusted to sarcopenia and its was associated with a OR = 8.44 (95% CI 3.85-18.4), P = 0.021, which demonstrates that these cut-off points remains associated after the adjustment with variables such as age, sex, cognitive impairment and comorbidity. Indeed, there are conflicting results on the association between PA and sarcopenia which can be explained by the diversity of the criteria used to define sarcopenia and the diversity of the population studied (older adults in the community, such as the population we used in this work, hospitalized elders, adults with some advanced disease such as kidney failure, liver cirrhosis, heart failure, among others).

The gait speed and muscle strength are two dimensions of physical frailty suggested by Fried et al. (6), which are closely related to sarcopenia. Our results show that cut-off points of ≤4.3° for adults 50 to 65 years and ≤4.1° for adults over 65 years are associated with frailty with an S = 91.95%, specificity 66.77%; AUROC = 0.9273 95% CI (0.8720-0.9825) and sensitivity = 72.37%, Sp= 71.43%; AUROC = 0.7925 95% CI (0.7280-0.8568), respectively by age group. In the model adjusted for age, sex, BMI, cognitive status and comorbidity, these cut-off points remained associated with an OR = 4.84 (2.61-8.99) P = 0.000, which shows that low PA is also associated with physical frailty and could be used for screening frailty when a BIA is available and a dynamometer is not. In this regard, the study by Mullie et al. (5) found a low PA (<4.5°, based on the first tertile of the population), has a high predictive capacity for postoperative mortality at one month, with an OR = 3.57 (1.35-9.47 95% CI) for each decrease of a PA degree. In another study of 4,667 people aged 60 years and over (4), in a low PA (first quintile) in women, the range of the first quintile was 2,655 to 5,419°, with a significant association, with an OR = 4.4 (95% CI 2.6−7-7), and in men the range of the first quintile of the PA was 3,070 to 5,646° with a significant association with an OR = 3.1 (95% CI 1.2-7-9). In this same study at 12 years of follow-up, low PA was associated with an HR = 2.4 (95% CI [95% CI] 1.8–3.1) in women and an HR = 2.2 (95% CI 1.7–2.9) in men, demonstrating the predictive capacity for frailty and mortality. The issue that makes it difficult to take the first quintile by sex is that different cut-off points must be taken into account for sex, age, among other variables, unlike in our article that proposes a single cut-off point adjusted by these same variables, which in the adjusted model remains significantly associated.

Some limitations were considered for this study; it is a cross-sectional study that does not allow assessing the temporality of the presentation of the variables, as well as limiting their predictive capacity. However, this study incorporates the new European criteria for sarcopenia adjusted to the Mexican population that could not be very comparable with previous studies because they included criteria of physical frailty of Fried et al. (6). However, an strength was to use the objective measures such as appendicular mass by DXA, gait speed by gait Rite® and hand grip strength by manual dynamometer (JAMAR®) to evaluate the main variables.

The cut-off points shown are not representative of the national context; however, since we do not have previous studies in this population, we believe that reporting a cut-off point of PA associated with sarcopenia and frailty contributes to establishing a criterion that can be used when the bioelectrical impedance is accessible (hospitals, nutricionist, medical and geriatrician offices).

Conclusion and Implications

A PA with a cut-off point of ≤4.3 in the adults 50 to 65 years and ≤4.1° in adults over 65 years, showed association and acceptable sensitivity for the screening for sarcopenia and frailty in men and women. The PA can be indicator effective in timely detecting conditions related to the functionality of the older adults, such as sarcopenia and frailty. It is important to evaluate these geriatric conditions because are they associated with a greater functional dependence, institutionalization, higher health costs, and mortality.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics Statement

The studies involving human participants were reviewed and approved by Ethics Committee of the National Institute of Geriatrics with the number DI-PI-002/2014. The patients/participants provided their written informed consent to participate in this study.

Author Contributions

ML-T and OR-C contributed to the data collection, original idea, data analysis, manuscript writing and revision. RR-V manuscript writing and revision. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Khalil SF, Mohktar MS, Ibrahim F. The theory and fundamentals of bioimpedance analysis in clinical status monitoring and diagnosis of diseases. Sensors. (2014) 14:10895–928. doi: 10.3390/s140610895

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Ward LC. Segmental bioelectrical impedance analysis: an update. Curr Opin Clin Nutr Metab Care. (2012) 15:424–9. doi: 10.1097/MCO.0b013e328356b944

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Ward LC, Müller M. Bioelectrical impedance analysis. Eur J Clin Nutr. (2013) 67 Suppl. 1:S1. doi: 10.1038/ejcn.2012.148

CrossRef Full Text | Google Scholar

4. Wilhelm-Leen ER, Hall YN, Horwitz RI, Chertow GM. Phase angle, frailty and mortality in older adults. J Gen Intern Med. (2014) 29:147–54. doi: 10.1007/s11606-013-2585-z

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Mullie L, Obrand A, Bendayan M, Trnkus A, Ouimet MC, Moss E, et al. Phase angle as a biomarker for frailty and postoperative mortality: the BICS study. J Am Heart Assoc. (2018) 7:e008721. doi: 10.1161/JAHA.118.008721

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Aging. (2019) 48:16–31. doi: 10.1093/ageing/afy169

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Pahor M, Kritchevsky SB, Waters DL, Villareal DT, Morley J, Hare JM, et al. Designing drug trials for frailty: ICFSR Task force 2018. J Frail Aging. (2018) 7:150–4. doi: 10.14283/jfa.2018.20

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. J Diab Metab Disord. (2017) 16:21. doi: 10.1186/s40200-017-0302-x

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Parra-Rodríguez L, Szlejf C, García-González AI, Malmstrom TK, Cruz-Arenas E, Rosas-Carrasco O. Cross-cultural adaptation and validation of the spanish-language version of the SARC-F to assess sarcopenia in Mexican community-dwelling older adults. J Am Med Direct Assoc. (2016) 17:1142–6. doi: 10.1016/j.jamda.2016.09.008

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Sánchez-Rodríguez D, Marco E, Miralles R, Fayos M, Mojal S, Alvarado M, et al. Sarcopenia, physical rehabilitation and functional outcomes of patients in a subacute geriatric care unit. Arch Gerontol Geriat. (2014) 59:39–43. doi: 10.1016/j.archger.2014.02.009

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Wilson D, Jackson T., Sapey E, Lord JM. Frailty and sarcopenia: The potential role of an aged immune system. Ageing Res Rev. (2017) 36:1–10. doi: 10.1016/j.arr.2017.01.006

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Basile C, Della-Morte D, Cacciatore F, Gargiulo G, Galizia G, Roselli M, et al. Phase angle as bioelectrical marker to identify elderly patients at risk of sarcopenia. Exp Gerontol. (2014) 58:43–6. doi: 10.1016/j.exger.2014.07.009

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Marini E, Buffa R, Saragat B, Coin A, Toffanello ED, Berton L, et al. The potential of classic and specific bioelectrical impedance vector analysis for the assessment of sarcopenia and sarcopenic obesity. Clin Interv Ag. (2012) 7:585–91. doi: 10.2147/CIA.S38488

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. (1998) 147:755–63. doi: 10.1093/oxfordjournals.aje.a009520

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Yamada M, Kimura Y, Ishiyama D, Nishio N, Otobe Y, Tanaka T, et al. Phase angle is a useful indicator for muscle function in older adults. J Nutr Health Aging. (2019) 23:251–5. doi: 10.1007/s12603-018-1151-0

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Kilic MK, Kizilarslanoglu MC, Arik G, Bolayir B, Kara O, Dogan Varan H, et al. Association of bioelectrical impedance analysis-derived phase angle and sarcopenia in older adults. Nutr Clin Prac. (2017) 32:103–9. doi: 10.1177/0884533616664503

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Santana NM, Pinho C, da Silva CP, Dos Santos NF, Mendes R. Phase angle as a sarcopenia marker in hospitalized elderly patients. Nutr Clin Prac. (2018) 33:232–7. doi: 10.1002/ncp.10016

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Norman K, Stobäus N, Zocher D, Bosy-Westphal A, Szramek A, Scheufele R, et al. Cutoff percentiles of bioelectrical phase angle predict functionality, quality of life, and mortality in patients with cancer. Am J Clin Nutr. (2010) 92:612–9. doi: 10.3945/ajcn.2010.29215

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Norman K, Stobäus N, Pirlich M, Bosy-Westphal A. Bioelectrical phase angle and impedance vector analysis–clinical relevance and applicability of impedance parameters. Clin Nutr. (2012) 31:854–61. doi: 10.1016/j.clnu.2012.05.008

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Rosas-Carrasco O, Cruz-Arenas E, Parra-Rodríguez L, García-González AI, Contreras-González LH, et al. Cross-Cultural adaptation and validation of the FRAIL scale to assess frailty in mexican adults. J Am Med Direct Assoc. (2016) 17:1094–8. doi: 10.1016/j.jamda.2016.07.008

CrossRef Full Text | Google Scholar

21. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Cardiovascular Health Study Collaborative Research Group (2001). Frailty in older adults: evidence for a phenotype. J Gerontol. (2017) 56:M146–56. doi: 10.1093/gerona/56.3.m146

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Stewart AL, Mills KM, King AC, Haskell WL, Gillis D, Ritter PL. CHAMPS physical activity questionnaire for older adults: outcomes for interventions. Med Sci Sports Exerc. (2001) 33:1126–41. doi: 10.1097/00005768-200107000-00010

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Salinas-Rodríguez A, Manrique-Espinoza B, Acosta-Castillo GI, Franco-Núñez A, Rosas-Carrasco O, Gutiérrez-Robledo LM, et al. Validación de un punto de corte para la versión breve de la Escala de Depresión del Centro de Estudios Epidemiológicos en adultos mayores mexicanos [Validation of a cutoff point for the short version of the Depression Scale of the Center for Epidemiologic Studies in older Mexican adults]. Salud Pub Mexico. (2014) 56:279–85. doi: 10.21149/spm.v56i3.7346

CrossRef Full Text | Google Scholar

24. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res. (1975) 12:189–98. doi: 10.1016/0022-3956(75)90026-6

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Ostrosky-Solís F, López-Arango G, Ardila A. Sensitivity and specificity of the Mini-Mental State Examination in a Spanish-speaking population. Appl Neuropsychol. (2000) 7:25–31. doi: 10.1207/S15324826AN0701_4

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dise. (1987) 40:373–83. doi: 10.1016/0021-9681(87)90171-8

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Rosas-Carrasco O, González-Flores E, Brito-Carrera AM, Vázquez-Valdez OE, Peschard-Sáenz E, Gutiérrez-Robledo LM, et al. Evaluación de la comorbilidad en el adulto mayor [Assessment of comorbidity in elderly]. Rev Med Insti Mexic Seguro Social. (2011) 49:153–62.

PubMed Abstract | Google Scholar

28. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. (1994) 49:M85–M94. doi: 10.1093/geronj/49.2.m85

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. (1969) 9:179–86.

PubMed Abstract | Google Scholar

30. Manohey FI, Barthel DW. Functional evaluation: the Barthel index. Maryland State Med J. (1965) 14:61–5.

PubMed Abstract | Google Scholar

31. World Health Organization. Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis: Report of a WHO Study Group [meeting held in Rome from 22 to 25 June 1992]. World Health Organization. (1994). Available online at: https://apps.who.int/iris/handle/10665/39142.

Google Scholar

32. Pessoa DF, de Branco F, Dos Reis AS, Limirio LS, Borges LP, Barbosa CD, et al. Association of phase angle with sarcopenia and its components in physically active older women. Aging Clin Exp Res. (2020) 32:1469–75. doi: 10.1007/s40520-019-01325-0

PubMed Abstract | CrossRef Full Text | Google Scholar

Keywords: phase angle, cut-off point, sarcopenia, frailty, older adults, sensitivity, specificity, validity

Citation: Rosas-Carrasco O, Ruiz-Valenzuela RE and López-Teros MT (2021) Phase Angle Cut-Off Points and Their Association With Sarcopenia and Frailty in Adults of 50–64 Years Old and Older Adults in Mexico City. Front. Med. 8:617126. doi: 10.3389/fmed.2021.617126

Received: 14 October 2020; Accepted: 12 February 2021;
Published: 15 March 2021.

Edited by:

Bagher Larijani, Tehran University of Medical Sciences, Iran

Reviewed by:

Tomasz Kostka, Medical University of Lodz, Poland
Fabrizia Lattanzio, National Institute of Science and Health for Aging (INRCA-IRCCS), Italy
Ramin Heshmat, Tehran University of Medical Sciences, Iran

Copyright © 2021 Rosas-Carrasco, Ruiz-Valenzuela and López-Teros. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Miriam T. López-Teros, bWlyaWFtLmxvcGV6JiN4MDAwNDA7aWJlcm8ubXg=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.